Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Latest Information Update: 29 Apr 2024
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Ewing's sarcoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 23 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 19 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 19 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.